🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This month at #EANO2024, we presented blinded safety data from our ongoing Phase 2b study of #IGV001 in patients with #glioblastoma. IGV-001 is the first product candidate developed with our Goldspire® platform. #CancerResearch

Our #Goldspire platform enables complete patient tumor tissue processing and product preparation in less than 24 hours, allowing for implantation into the patient the next day. Learn more about the advantages of Goldspire®: bit.ly/3Y7GshO

This weekend at #SITC2024, Imvax CSO Mark A. Exley, Ph.D. will present data on the use of our Goldspire® platform to enable durable and system immunity in multiple solid cancer types. Stop by his poster on Saturday, Nov 9th! #Goldspire #cancerresearch

We are proud to be a part of the #STEM community, which makes up approximately 25% of the U.S. workforce. This #NationalSTEMDay, hear from some of our team on why they decided to pursue a career in STEM and the value of STEM education:

We will present oral and poster presentations on the development of our lead candidate #IGV001 at the 2024 SNO Annual Meeting next week. Details: bit.ly/48LCoaq SNO #SNO2024 #braincancer #cancerresearch

#Goldspire fits within the SOC for patients with resectable solid tumors. After the biodiffusion chamber implant/removal process, the patient’s immune system training begins & they can continue with the SOC. Learn more: bit.ly/3Y7GshO

If you are at #SNO2024 this week, we invite you to stop by our symposium today at 12:45 pm CST. We have a great agenda planned, featuring an overview of #Goldspire & the latest developments around our lead candidate #IGV001 for #GBM. Reach out to us for more details.

We’re on the ground at #SNO2024! Stop by our booth at the George R. Brown Convention Center in Houston to connect with our team. #cancerresearch #braincancer #neurooncology #glioblastoma #IGV001 #Goldspire

Happy Thanksgiving to our incredible team and partners!

This week in Boston, Imvax CMO David Andrews, M.D. and COO Sean Hemingway will present on the development and manufacturing of IGV-001 at the Personalized Cancer Vaccine Summit. For more about the event: bit.ly/3ObKkrU #IGV001 #Goldspire #immunooncology #cancerresearch

We’re committed to developing a new approach to treating #glioblastoma. Learn more about our lead product candidate, #IGV001, for patients with newly diagnosed #GBM, now in a Phase 2b trial: bit.ly/4hPAIAM

Happy Holidays from Team Imvax! Wishing everyone a restful and joyous holiday season. We look forward to continuing our work for #glioblastoma patients in the new year!

2024 was filled with special moments, from IGV-001 receiving Fast Track designation by the #FDA to presenting on the development of #IGV001 at #ESMO24, #SITC24 & #SNO24. We look forward to an exciting 2025 as we plan to announce results from our Ph. 2b trial of IGV-001 in #GBM.

Members of the Imvax leadership team have touched down in San Francisco for #JPM25. We look forward to engaging in discussions with investors and key industry players around what’s in store for #biotech and Imvax in 2025.

#Glioblastoma is a complex and deadly brain cancer that affects over 14,000 people in the U.S. each year. Learn more about this devastating #braincancer and the need for innovative treatments like IGV-001 here: bit.ly/3Dc2Mi2 #IGV001 #GBM #cancerresearch

Today we announced the completion of a $29 million financing round. We are also on track to report topline results from our Phase 2b trial of #IGV001 in patients with newly diagnosed #glioblastoma in mid-2025. More: bit.ly/3CtPrBx

Today on #WorldCancerDay we’re emphasizing the importance of people-centered care. Visit Imvax partner Head For The Cure to read about some inspiring journeys of resilience and hope from brain cancer patients: bit.ly/40CkO6n #UnitedByUnique

IGV-001 is a personalized therapy that aims to induce antitumor immunity in newly diagnosed patients with #GBM. It includes the patient’s own tumor cells plus a molecule called IMV-001 placed into biodiffusion chambers that are implanted in the patient. bit.ly/4itJkgJ

This International Day of Women and Girls in Science, we’re celebrating Amanda Bucolo and Taylor Smith – two women shaping our science here at Imvax. See below for their insights on what it’s like being #WomenInScience. #IDWGS2025

Join Head of Clinical Development and Medical Affairs Raul Perez-Olle, M.D., Ph.D. at the 6th Annual @GBMSummit as he shares key learnings from the development of #IGV001. See the full session details here: bit.ly/3PIgkVe #glioblastoma #braincancer